Template:Trichomonas antibiotics: Difference between revisions
(→Men) |
|||
| Line 8: | Line 8: | ||
====Sexual Partner Treatment==== | ====Sexual Partner Treatment==== | ||
* | *Female: Same as above | ||
*Male: [[Metronidazole]] 2 gm PO x1 <ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon </ref> | *Male: [[Metronidazole]] 2 gm PO x1 <ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon </ref> | ||
Revision as of 22:43, 19 June 2024
Non-Pregnant
- Metronidazole 500mg PO BID for 7 days [1]
- Tinidazole 2g PO once
Pregnant
Only treat if the patient is symptomatic and avoid breast feeding until 24-hrs after last dose
- Metronidazole 2g PO once[2]
Sexual Partner Treatment
- Female: Same as above
- Male: Metronidazole 2 gm PO x1 [3]
- ↑ Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon
- ↑ CDC Trichomoniasis 2015. https://www.cdc.gov/std/tg2015/trichomoniasis.htm
- ↑ Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon